Building multidimensional biomarker views of type 2 diabetes on the basis of protein microheterogeneity

Clinical Chemistry

Volumn 57, Issue 5, 2011, Pages 719-728

  Borges, Chad R ^a   Oran, Paul E ^a   Buddi, Sai ^b   Jarvis, Jason W ^a   Schaab, Matthew R ^a   Rehder, Douglas S ^a   Rogers, Stephen P ^a,c   Taylor, Thomas ^a   Nelson, Randall W ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b AZ 85281   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; APOLIPOPROTEIN A1; C REACTIVE PROTEIN; HEMOGLOBIN A1C; RANTES; VITAMIN D BINDING PROTEIN;

ARTICLE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE MARKER; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; IMMUNOASSAY; MASS SPECTROMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; OXIDATIVE STRESS; PROTEIN GLYCOSYLATION; PROTEIN POLYMORPHISM;

BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; GLYCOSYLATION; HEART FAILURE; HUMANS; IMMUNOASSAY; MYOCARDIAL INFARCTION; OXIDATION-REDUCTION; POINT MUTATION; PRINCIPAL COMPONENT ANALYSIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOME; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 79956082861     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.156976     Document Type: Article

References (40)

1. Brunner EJ, Shipley MJ, Witte DR, Fuller JH, Marmot MG. Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care 2006;29:26-31. (Pubitemid 44033426)
2. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33 Suppl 1:S62-9.
3. Bierman EL. George Lyman Duff Memorial Lecture: Atherogenesis in diabetes. Arterioscler Thromb 1992;12:647-56.
4. Libby P, Plutzky J. Diabetic macrovascular disease: the glucose paradox? Circulation 2002;106:2760-3.
5. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421-31.
6. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010;362:800-11.
7. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59. (Pubitemid 351831356)
8. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39.
9. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72. (Pubitemid 351831357)
10. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170:1191-201.
11. FOA. FDA guidance for industry: diabetes mellitus: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2008.
12. Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW. Investigating diversity in human plasma proteins. Proc Natl Acad Sci U S A 2005;102:10852-7. (Pubitemid 41105956)
13. Niederkofler EE, Tubbs KA, Gruber K, Nedelkov D, Kiernan UA, Williams P, Nelson RW. Determination of beta-2 microglobulin levels in plasma using a high-throughput mass spectrometric immunoassay system. Anal Chem 2001;73:3294-9. (Pubitemid 32880612)
14. Niederkofler EE, Tubbs KA, Kiernan UA, Nedelkov D, Nelson RW. Novel mass spectrometric immunoassays for the rapid structural characterization of plasma apolipoproteins. J Lipid Res 2003;44:630-9. (Pubitemid 37279713)
15. Borges CR, Jarvis JW, Oran PE, Rogers SP, Nelson RW. Population studies of intact vitamin D binding protein by affinity capture ESI-TOF-MS. J Biomol Tech 2008;19:167-76.
16. Borges CR, Rehder DS, Jarvis JW, Schaab MR, Oran PE, Nelson RW. Full-length characterization of proteins in human populations. Clin Chem 2010;56:202-11.
17. Kiernan UA, Addobbati R, Nedelkov D, Nelson RW. Quantitative multiplexed C-reactive protein mass spectrometric immunoassay. J Proteome Res 2006;5:1682-7. (Pubitemid 44036142)
18. Kiernan UA, Nedelkov D, Nelson RW. Multiplexed mass spectrometric immunoassay in biomarker research: a novel approach to the determination of a myocardial infarct. J Proteome Res 2006;5:2928-34. (Pubitemid 44749211)
19. Kiernan UA, Nedelkov D, Tubbs KA, Niederkofler EE, Nelson RW. Proteomic characterization of novel serum amyloid P component variants from human plasma and urine. Proteomics 2004;4:1825-9. (Pubitemid 38738336)
20. Oran PE, Sherma ND, Borges CR, Jarvis JW, Nelson RW. Intrapersonal and populational heterogeneity of the chemokine RANTES. Clin Chem 2010;56:1432-41.
21. Nedelkov D, Tubbs KA, Niederkofler EE, Kiernan UA, Nelson RW. High-throughput comprehensive analysis of human plasma proteins: a step toward population proteomics. Anal Chem 2004;76:1733-7. (Pubitemid 38338422)
22. Jaleel A, Halvatsiotis P, Williamson B, Juhasz P, Martin S, Nair KS. Identification of Amadorimodified plasma proteins in type 2 diabetes and the effect of short-term intensive insulin treatment. Diabetes Care 2005;28:645-52. (Pubitemid 40315326)
23. Bar-Or D, Heyborne KD, Bar-Or R, Rael LT, Winkler JV, Navot D. Cysteinylation of maternal plasma albumin and its association with intrauterine growth restriction. Prenat Diagn 2005;25:245-9. (Pubitemid 40478012)
24. Kiernan UA, Nedelkov D, Niederkofler EE, Tubbs KA, Nelson RW. High-throughput affinity mass spectrometry. Methods Mol Biol 2006;328:141-50.
25. Jolliffe IT. Principal component analysis. Springer-Verlag, 1986:78-108pp.
26. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-77. (Pubitemid 23118304)
27. Reaven GM. Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes 1988;37:1595-607. (Pubitemid 19004941)
28. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-25. (Pubitemid 40770750)
29. Stump CS, Clark SE, Sowers JR. Oxidative stress in insulin-resistant conditions: cardiovascular implications. Treat Endocrinol 2005;4:343-51. (Pubitemid 41751170)
30. Mashima R, Yamamoto Y, Yoshimura S. Reduction of phosphatidylcholine hydroperoxide by apolipoprotein A-I: purification of the hydroperoxide-reducing proteins from human blood plasma. J Lipid Res 1998;39:1133-40. (Pubitemid 28270076)
31. Shao B, Cavigiolio G, Brot N, Oda MN, Heinecke JW. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc Natl Acad Sci U S A 2008;105:12224-9.
32. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004;95:764-72. (Pubitemid 39390578)
33. McIntosh CH, Demuth HU, Kim SJ, Pospisilik JA, Pederson RA. Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus. Int J Biochem Cell Biol 2006;38:860-72. (Pubitemid 43363417)
34. Oran PE, Jarvis JW, Borges CR, Nelson RW. C-peptide microheterogeneity in type 2 diabetes populations. Proteomics Clin Appl 2010;4:1-6.
35. Niederkofler EE, Kiernan UA, O'Rear J, Menon S, Saghir S, Protter AA, et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail 2008;1:258-64.
36. Rasmussen HB, Branner S, Wiberg FC, Wagtmann N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol 2003;10:19-25. (Pubitemid 36034172)
37. Brandt I, Lambeir AM, Maes MB, Scharpe S, De Meester I. Peptide substrates of dipeptidyl peptidases. In: Lendeckel U, Reinhold D, Bank U, eds. Dipeptidyl aminopeptidases: basic science and clinical applications. Springer Science Business Media, 2006:3-18.
38. Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 1999;19:472-84. (Pubitemid 29135144)
39. Tall AR. An overview of reverse cholesterol transport. Eur Heart J 1998;19 Suppl A:A31-5.
40. Spady DK. Reverse cholesterol transport and atherosclerosis regression. Circulation 1999;100:576-8. (Pubitemid 29379743)